Tissue plasminogen activator; identifying major barriers related to intravenous injection in ischemic acute cerebral infraction

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

tissue plasminogen activator; identifying major barriers related to intravenous injection in ischemic acute cerebral infraction

background: in patients with acute ischemic cerebral infarction, thrombolytic therapy using intravenous tissue plasminogen activator (iv?tpa) necessitates precise documentation of symptoms’ onset. the aim of this study was to identify major barriers related to the iv?tpa injection in such patients. materials and methods: between 2014 and 2015, patients with definitive diagnosis of acute cerebra...

متن کامل

The Outcome of Treatment With Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke

Background: Thrombolytic therapy is the recommended treatment of acute ischemic stroke. It is crucial to evaluate the treatment results with recombinant Tissue Plasminogen Activator (r-TPA) in patients with acute stroke. Objectives: This study aimed to evaluate treatment outcomes with r-TPA in patients with acute stroke in a referral stroke center in Iran. Materials & Methods: In this retrosp...

متن کامل

Imaging Evidence for Cerebral Hyperperfusion Syndrome after Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke

Background. Cerebral hyperperfusion syndrome (CHS), a rare complication after cerebral revascularization, is a well-described phenomenon after carotid endarterectomy or carotid artery stenting. However, the imaging evidence of CHS after intravenous tissue plasminogen activator (iv tPA) for acute ischemic stroke (AIS) has not been reported. Case Report. Four patients were determined to have mani...

متن کامل

Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke.

IMPORTANCE Randomized clinical trials suggest the benefit of intravenous tissue-type plasminogen activator (tPA) in acute ischemic stroke is time dependent. However, modest sample sizes have limited characterization of the extent to which onset to treatment (OTT) time influences outcome; and the generalizability of findings to clinical practice is uncertain. OBJECTIVE To evaluate the degree t...

متن کامل

Thrombectomy with Soutenir for acute ischemic stroke patients unresponsive to intravenous recombinant tissue plasminogen activator

Intravenous (IV) administration of recombinant tissue plasminogen activator (rtPA) within 3 hours of symptom onset in patients with acute ischemic stroke has been proven to be an effective treatment. However, IV rtPA alone is occasionally insufficient to treat severe neurological deficit due to persistent major vascular occlusion. Since early recanalization is directly correlated with functiona...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Journal of Research in Medical Sciences

سال: 2017

ISSN: 1735-1995

DOI: 10.4103/1735-1995.200318